332 related articles for article (PubMed ID: 25808018)
1. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
[TBL] [Abstract][Full Text] [Related]
2. Unbound fraction of ertapenem in intensive care unit patients.
Liebchen U; Kratzer A; Wicha SG; Kees F; Kloft C; Kees MG
J Antimicrob Chemother; 2014 Nov; 69(11):3108-11. PubMed ID: 24962030
[TBL] [Abstract][Full Text] [Related]
3. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
[TBL] [Abstract][Full Text] [Related]
4. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study).
Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Gilder E; Kim HS; Lim SY; McGuinness S; Parke R; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA;
Clin Pharmacokinet; 2022 Jun; 61(6):847-856. PubMed ID: 35253107
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.
Bos JC; Prins JM; Mistício MC; Nunguiane G; Lang CN; Beirão JC; Mathôt RAA; van Hest RM
J Antimicrob Chemother; 2018 Jun; 73(6):1620-1629. PubMed ID: 29522167
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
8. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?
Ollivier J; Carrié C; d'Houdain N; Djabarouti S; Petit L; Xuereb F; Legeron R; Biais M; Breilh D
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602511
[TBL] [Abstract][Full Text] [Related]
9. Unbound fraction of vancomycin in intensive care unit patients.
Kees MG; Wicha SG; Seefeld A; Kees F; Kloft C
J Clin Pharmacol; 2014 Mar; 54(3):318-23. PubMed ID: 24000044
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.
Joynt GM; Lipman J; Gomersall CD; Young RJ; Wong EL; Gin T
J Antimicrob Chemother; 2001 Apr; 47(4):421-9. PubMed ID: 11266414
[TBL] [Abstract][Full Text] [Related]
12. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.
Simon N; Dussol B; Sampol E; Purgus R; Brunet P; Lacarelle B; Berland Y; Bruguerolle B; Urien S
Clin Pharmacokinet; 2006; 45(5):493-501. PubMed ID: 16640454
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
Fish DN
Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
[TBL] [Abstract][Full Text] [Related]
16. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury.
Markowsky SJ; Skaar DJ; Christie JM; Eyer SD; Ehresman DJ
Ann Pharmacother; 1996 May; 30(5):443-8. PubMed ID: 8740320
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy.
Goto K; Sato Y; Yasuda N; Hidaka S; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Itoh H
J Basic Clin Physiol Pharmacol; 2016 Nov; 27(6):625-631. PubMed ID: 27497425
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the relationship between serum and milk residue disposition of ceftriaxone in lactating ewes.
Goudah A; Shin HC; Shim JH; Abd El-Aty AM
J Vet Pharmacol Ther; 2006 Aug; 29(4):307-12. PubMed ID: 16846468
[TBL] [Abstract][Full Text] [Related]
20. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
